5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

ring A is a 5-7 membered nitrogen-containing heterocyclyl, optionally substituted by an oxo group;

each R is independently C 1-6 alkyl, optionally substituted by one or more substituents independently selected from the group consisting of R b1 and R c1 ;

each R b1 is independently selected from the group consisting of —OR c1 and —C(O)OR c1 ;

each R c1 is independently selected from the group consisting of hydrogen, 3-10 membered heterocyclyl and C 1-6 alkyl, wherein the C 1-6 alkyl is optionally substituted by a 3-10 membered heterocyclyl; and

q is 0, 1 or 2.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

ring A is selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, 1,4-diazepanyl and 1,4-oxazepanyl, each optionally substituted by an oxo group.

3. The compound according to claim 2 , or a pharmaceutically acceptable salt thereof, wherein:

ring A is selected from the group consisting of piperazinyl, piperazinonyl and morpholinyl.

4. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein:

ring A is selected from the group consisting of piperazin-1-yl, 2-oxopiperazin-4-yl and morpholin-4-yl.

5. The compound according to claim 4 , or a pharmaceutically acceptable salt thereof, wherein:

ring A is piperazin-1-yl.

6. The compound according to claim 5 , or a pharmaceutically acceptable salt thereof, wherein:

ring A is piperazin-1-yl; and

q is 0, 1 or 2;

with the proviso that if q is 1 or 2, at least one R is bonded to the 4-position of the piperazin-1-yl.

7. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each R is independently C 1-6 alkyl, optionally substituted by —OH or —OCH 3 .

8. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

each R is independently selected from the group consisting of CH 3 and CH 2 CH 3 , wherein each CH 3 and CH 2 CH 3 is independently substituted by a substituent independently selected from the group consisting of —C(O)OR c1 and 5-6 membered heterocyclyl; and

each R c1 is independently selected from the group consisting of 5-6 membered heterocyclyl and CH 3 , wherein the CH 3 is substituted by a 5-6 membered heterocyclyl.

9. The compound according to claim 8 , or a pharmaceutically acceptable salt thereof, wherein:

each R is independently substituted by a substituent selected from the group consisting of pyrrolidinyl, tetrahydrofuryl and tetrahydropyranyl.

10. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

q is 1.

11. The compound according to claim 10 , or a pharmaceutically acceptable salt thereof, wherein:

R is bonded to a nitrogen atom of ring A.

12. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

q is 0.

13. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising at least one compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition according to claim 14 , wherein the pharmaceutical composition further comprises one or more additional cytostatic or cytotoxic active substances.

16. A method for inhibiting insulin-like growth factor-1 receptor activity or insulin receptor activity in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

17. The method according to claim 16 , wherein the subject has a disease or condition wherein the inhibition of insulin-like growth factor-1 or insulin receptor is of therapeutic benefit selected from the group consisting of a solid tumor, a viral infection, a bacterial infection, a fungal infection, a parasitic infection, an inflammatory disease, an autoimmune disease, a bone disease, a skin disease, a cardiovascular disease, a disease based on hyperplasia which is characterized by an increase in the number of cells, and cancer.

18. The method according to claim 17 , wherein the cancer is intrinsically dependent on oncogenic signaling via the insulin-like growth factor-1 receptor and/or insulin receptor.